Ignite Creation Date:
2024-05-06 @ 5:23 PM
Last Modification Date:
2024-10-26 @ 2:27 PM
Study NCT ID:
NCT05287139
Status:
UNKNOWN
Last Update Posted:
2022-03-18
First Post:
2022-03-10
Brief Title:
QOL of Women With HR-Positive Metastatic BC Treated in the First-line Setting Comparison Between Public and Private Institutions
Sponsor:
Beneficência Portuguesa de São Paulo
Organization:
Beneficência Portuguesa de São Paulo
Study Overview
Official Title:
Quality of Life of Women With Hormone Receptor-Positive Metastatic Breast Cancer Treated in the First-line Setting Comparison Between Public and Private Institutions
Status:
UNKNOWN
Status Verified Date:
2022-03
Last Known Status:
ENROLLING_BY_INVITATION
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BRAVE
Brief Summary:
Assess the quality of life in patients with hormone receptor positive human epidermal growth factor receptor-type 2 negative metastatic breast cancer treated in first line patients with new metastasis or recurrence during adjuvant endocrine therapy comparison between public and private institutions The hypothesis to be evaluated is that patients treated in private institutions have a better quality of life when compared to patients treated in public institutions
Detailed Description:
The main objective of the study is to assess the quality of life using the EORTC-QLQ-C30 EORTC Quality of Life Questionnaire and the EORTC-QLQ-BR23 EORTC Quality of Life Questionnaire - Breast Cancer of a patient with metastatic breast cancer hormone receptor positive human epidermal growth factor receptor-type 2 negative receiving treatment in the first-line scenario comparing public and private institutions
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None